Literature DB >> 34656817

Comparing characteristics and outcomes of different opioid agonist treatment modalities among opioid-dependent federal men correctional populations in Canada.

Shanna Farrell MacDonald1, Cayley Russell2, Tara Beauchamp3, Dena Derkzen3, Benedikt Fischer4.   

Abstract

BACKGROUND: Limited evidence exists in Canada on outcomes related to Opioid Agonist Treatment (OAT) and/or differences between OAT modalities among persons in correctional institutions. This study addresses this knowledge gap by examining key characteristics and outcomes of men in Canadian federal correctional institutions across treatment modalities.
METHODS: A retrospective cohort of men incarcerated in federal correctional institutions (N = 2833) were classified into four groups - three OAT participant groups: prescribed methadone (M-OAT), prescribed buprenorphine/naloxone (Suboxone®; S-OAT) and those who switched between the two OAT modalities at least once (X-OAT). The fourth group was a non-treatment comparison group (Non-OAT). Two-thirds of study participants were released and examined for post-release outcomes. Descriptive statistics and multi-variate Cox proportional hazards regression were used.
RESULTS: The X-OAT group was more likely than the other study groups to have positive urinalysis tests, disciplinary charges, or institutional security or behavioral incidents. Survival analysis indicated that the X-OAT had an adjusted hazard of a return to custody that was 57% greater than the other groups.
CONCLUSIONS: This study indicates that individuals switching OAT modalities are a more complex group needing additional supports, especially for community reintegration. Although few of the returns to custody were due to new offences, a third of participants in the OAT groups had their release revoked, indicating a high need population mostly due to their substance use.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Buprenorphine/naloxone (Suboxone®); Canada; Corrections; Methadone; Opioids agonist treatment; Release

Mesh:

Substances:

Year:  2021        PMID: 34656817     DOI: 10.1016/j.drugpo.2021.103480

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  2 in total

1.  Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison.

Authors:  Michael Curtis; Justin Berk; Sarah Larney; Josiah D Rich; Mark Stoové
Journal:  Int J Drug Policy       Date:  2022-01-05

2.  Substance-Specific Risk Factors for Cannabis and Alcohol Use Among Young Adults Following Implementation of Nonmedical Cannabis Legalization.

Authors:  Michael S Gilson; Jason R Kilmer; Charles B Fleming; Isaac C Rhew; Brian H Calhoun; Katarina Guttmannova
Journal:  Prev Sci       Date:  2022-09-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.